Phase I Randomized Trial of Stereotactic Body Radiotherapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

CONCLUSIONS: In this first prospective trial investigating the combination of SBRT and immunotherapy for HCC, multi-modal therapy demonstrated acceptable safety. SBRT with nivolumab plus ipilimumab compared favorably to outcomes of immunotherapy alone and warrants further investigation.PMID:36108891 | DOI:10.1016/j.ijrobp.2022.09.052

Source: Cancer Control - September 15, 2022 Category: Cancer & Oncology Authors: Aditya Juloori Rohan R Katipally Jeffrey M Lemons Anurag K Singh Renuka Iyer Jared R Robbins Ben George William A Hall Sean P Pitroda Fauzia Arif John Fung Anjana Pillai Chih-Yi Liao Manish Sharma Stanley L Liauw Source Type: research